Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis [PDF]
Терапевтический архив, 2019 Aim. Сomparative studying of changes in the spectrum of bile acids in bile in patients with nonalcoholic fatty liver disease and cholelithiasis. Materials and methods.
Ya M Vakhrushev +3 more
doaj +1 more source
Oxidative stress: new insights on the association of nonalcoholic fatty liver disease and atherosclerosis [PDF]
, 2015 Non-alcoholic fatty liver disease (NAFLD) represents the most common and emerging chronic liver disease worldwide. It includes a wide spectrum of liver diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH), which may progress ...
Albanese, Fabiana +7 more
core +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Львівський клінічний вісник, 2015 Introduction. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases where its frequency in the population varies within 3.0–40.0 %.
Mashura H., Hanych T.
doaj +1 more source
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments [PDF]
Clinical and Molecular Hepatology, 2023 Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis.
Sang Bong Ahn
doaj +1 more source
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets [PDF]
, 2013 Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children. NAFLD has emerged to be extremely prevalent, and predicted by obesity and male gender.
Giorgio V +3 more
core +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Hepatology, EarlyView., 2022 Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
Repurposing drugs to target nonalcoholic steatohepatitis [PDF]
, 2019 Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage.
Pirola, Carlos José +1 more
core +1 more source
Hepatology Communications, EarlyView., 2022 Abstract Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence and severity globally, prompting noninvasive testing, yet limited data exist on noninvasive liver tests (NITs) including transient elastography (TE) in ethnically diverse populations.
Anne‐Marieke van Dijk +6 more
wiley +1 more source
Nonalcoholic Fatty Liver Disease in Children: a Modern View on the Diagnosis and Treatment (II Part)
Gastroenterologìa, 2015 In Part II methods of research and treatment of nonalcoholic fatty liver disease in children are highlighted, which are based on the evidence. Ultrasound examination of the liver is the most common method for diagnosis of nonalcoholic fatty liver disease
Y.M. Stepanov +3 more
doaj +1 more source